Phaseline

Companies › Atsena Therapeutics

Atsena Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Ophthalmology, Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATSN-201
AAV gene therapy delivering hRS1 under hGRK1 promoter
RS1Phase 3X-linked RetinoschisisApr 2028
ATSN-101
Gene therapy for GUCY2D mutations
GUCY2DPhase 1Leber Congenital AmaurosisMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03920007ATSN-101Phase 1Leber Congenital AmaurosisOphthalmologyMay 2027
NCT05878860ATSN-201Phase 3X-linked RetinoschisisOtherApr 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GUCY2D (1) RS1 (1)

Companies with the same targets

–

Companies built like this

EnnovaBio Novadip Biosciences Harmony Biosciences Management Bausch & Lomb Ocugen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.